Affymax says to continue studying anemia drug
Aug 7 (Reuters) - Affymax Inc (AFFY.O: Quote, Profile, Research, Stock Buzz) said an independent data monitoring committee has determined that the company can continue studying its anemia drug in late-stage trials.
Hematide is being evaluated to treat anemia in chronic renal failure patients on dialysis and not on dialysis.
Shares of Affymax closed at $20.40 Thursday on Nasdaq. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Anil D'Silva)
© Thomson Reuters 2008 All rights reserved
Ads by Career Builder
Registered Healthcare Architect A.I.A
Details: ...is looking for a Healthcare Project Manager...industries include: Healthcare, Research, K-12...Architect in Arizona - Healthcare experience is a...
Healthcare Specialist / Inbound / Outbound
Details: Healthcare / Specialist / Sales Healthcare Specialist / Inbound...applications for Healthcare Inbound / Outbound...
Healthcare Recruiter/Entry-Level Sales Management
Details: Maxim Healthcare Services is one...leader in the healthcare industry through...industry. Maxim Healthcare Services is recognized...
Healthcare / Hospital / Medical Construction Management
Details: ...candidates for Healthcare / Hospital / Medical...Manager, Architect, Healthcare Planner, Business...exploring the Atlanta Healthcare / Hospital / Medical...
Bill Clinton
Obama nominated by acclamation
